Keytruda is the best-selling drug in the world, and its price is unusually easy to pin down because three separate authorities publish it and they land within 1.2% of each other. Merck states a list price on its own patient site, discloses a wholesale acquisition cost under Colorado law, and Medicare publishes a quarterly payment limit for the billing code. All three say the same thing: about $12,000 for one dose.
What is harder to pin down is what an uninsured person actually gets billed, because the drug is bought by the practice and marked up before it reaches your statement. Those two numbers are more than two times apart, and the gap is where almost all of the negotiating room lives. Every figure below was researched on September 3, 2026.
What Does Keytruda Cost Without Insurance?
The Medicare column comes from the CMS Part B payment limit file effective July 1 through September 30, 2026, which sets J9271 (pembrolizumab) at $60.645 per mg and the subcutaneous J9277 at $31.940 per mg. That file resets on October 1, 2026. Manufacturer figures come from Merck’s Colorado wholesale acquisition cost disclosure and Merck’s own patient site, both stating a list price current as of March 2026. Gross charges are the national average submitted charge from CMS claims data for 2024, the most recent year published.
| Keytruda purchase | Low | Average | High |
|---|---|---|---|
| One 100 mg IV vial | $6,064.50 | $6,100.25 | $6,136.00 |
| 200 mg IV dose, every 3 weeks | $12,129.00 | $12,200.50 | $12,272.00 |
| 400 mg IV dose, every 6 weeks | $24,258.00 | $24,401.00 | $24,544.00 |
| Keytruda Qlex 395 mg subcutaneous, every 3 weeks | $12,272.00 | $12,444.15 | $12,616.30 |
| Keytruda Qlex 790 mg subcutaneous, every 6 weeks | $24,544.00 | $24,888.30 | $25,232.60 |
| One year of drug, 17 to 18 three-week doses | $206,193 | $213,545 | $220,896 |
| Infusion administration, CPT 96413 first hour | $125.21 | $337.46 | $481.33 |
| What a practice bills an uninsured patient per 200 mg dose | $27,201.70 | $27,201.70 | $27,201.70 |
| Opdivo (nivolumab) 240 mg dose, every 2 weeks | $7,943.08 | $8,078.18 | $8,213.28 |
| Merck co-pay card, private insurance only | $25 | $25 | $25 |
Read that gross-charge row carefully, because it is the one that shows up on a self-pay statement. Providers submit an average of $136.01 per mg for J9271 against a Medicare allowed amount of $55.28 per mg in the same 2024 data. At 200 mg that is $27,201.70 billed against $11,056.12 allowed. Add the $481.33 average submitted charge for the infusion itself and a single uninsured Keytruda visit gets billed around $27,700.
The administration row spans the three places you can sit for the infusion. A physician office is paid about $125 by Medicare for CPT 96413, a hospital outpatient department is paid $337.46 under ambulatory payment classification 5694 in the July 2026 outpatient addendum, and the average charge submitted nationally is $481.33. Keytruda infuses over 30 minutes per the FDA label, so the first-hour code is usually the only administration code on the claim.
What Drives the Price
There is no biosimilar and no second source. FDA’s Drugs@FDA database returns exactly two pembrolizumab applications, both Merck’s: BLA 125514 for the IV product and BLA 761467 for Keytruda Qlex. Nothing competes on price, and no pharmacy substitution is possible.
The vial size sets the floor. Keytruda ships as a 100 mg single-use vial, so a 200 mg dose is two vials and there is no partial-fill option. Merck’s disclosed wholesale acquisition cost is $6,136.00 for one vial and $12,272.00 for a carton of two.
Buy-and-bill markup is where the uninsured price is made. The practice or hospital purchases the drug, then bills you its own charge. Nationally that charge averages 2.5 times the Medicare allowed amount for this specific code, which is why the $12,000 drug lands on a $27,000 statement.
Where you sit changes the administration fee by 2.7 times. The same 30 minutes in a chair is $125 in a physician office and $337.46 in a hospital outpatient department under Medicare’s own rates. Hospital-owned infusion suites that look identical to independent ones bill at the hospital rate.
Subcutaneous does not mean cheaper. Keytruda Qlex, the pembrolizumab plus berahyaluronidase alfa injection, is a one-minute or two-minute injection instead of a 30-minute infusion. Merck lists it at exactly the same price as the matching IV dose, and Medicare’s July 2026 payment limit is about 4% higher for the subcutaneous version ($12,616.30 for 395 mg) than for IV ($12,129.00 for 200 mg). The upside is time, not money.
The competing drug costs the same per year. Opdivo (nivolumab, code J9299) is $34.222 per mg in the July 2026 Medicare file against pembrolizumab’s $60.645, which looks like a bargain until you account for dosing. BMS lists the 240 mg vial at $7,943.08, and the every-two-week schedule means 26 doses a year. That is $206,520 to $213,545 annually, essentially indistinguishable from Keytruda. Note that BMS footnotes its price page to 2024 data on file, so it is the least fresh figure on this page.
Cash Price vs. Insurance
There is no meaningful cash discount on Keytruda. It is not a pharmacy drug you can shop with a discount card, it is a buy-and-bill medical benefit drug, and the person setting your price is the infusion center rather than a pharmacy chain.
The co-pay card is worthless to you if you are uninsured, and Merck says so plainly. The Merck Co-pay Assistance Program terms require private health insurance that covers the drug under a medical or pharmacy benefit, cap the benefit at $25,000 per year, and state that the program is not valid for uninsured patients or for anyone on Medicaid, Medicare, or any other state or federal program. Eligible commercially insured patients pay the first $25 per administration.
The route that does exist for the uninsured is free drug. The Merck Patient Assistance Program supplies Keytruda at no cost to US residents who cannot afford it, and the stated household income ceilings are $79,800 for an individual, $108,200 for a couple, and $165,000 for a family of four. Those are unusually generous ceilings by patient assistance standards, well above the levels most programs use, and they are the single most important number on this page if you have no coverage.
One caution: patient assistance covers the drug, not the visit. You can be approved for free Keytruda and still owe the infusion center for the chair, the nursing time, the labs, and the imaging.
How to Pay Less
Apply to the Merck Patient Assistance Program before your first infusion. Call the Merck Access Program at 855-257-3932 and ask specifically for the patient assistance program, not the savings card. At $12,000 a dose, this is the highest-value phone call available to you, and approval is not instant, so start before treatment rather than after the first bill.
Get treated in a physician office or freestanding infusion center rather than a hospital outpatient department. Medicare’s own rates put the same administration at $125 versus $337.46. Ask directly whether the infusion suite bills as a hospital outpatient department, because many that look like private offices do. Our guide to hospital price transparency explains how to look up a specific facility’s posted rates before you commit.
Ask for the itemized bill and check the drug line against the Medicare rate. The J9271 line is the entire bill. If it is billed at more than twice $60.645 per mg, you have a concrete, documented number to negotiate against. See how to read an itemized hospital bill and how to negotiate medical bills for the exact language.
File for charity care at the same time, not afterward. Nonprofit hospitals must have a written financial assistance policy, and oncology bills routinely qualify people who assume they earn too much. Start with hospital charity care and run your numbers through the charity care check tool.
Ask whether a 340B-priced site is available. Federally qualified health centers and disproportionate-share hospitals buy Part B drugs at deep statutory discounts, and some pass that through on a sliding scale. Free and sliding-scale clinics covers how to find one and what to ask.
Ask whether the every-six-week schedule fits. The FDA label allows 400 mg every six weeks as an alternative to 200 mg every three weeks. The drug cost per year is the same, but you pay half as many administration fees and make half as many trips. That is a clinical decision for your oncologist, but it is a fair cost question to raise.
The Bottom Line
Keytruda is a $12,129 to $12,272 purchase every three weeks and a $206,193 to $220,896 purchase every year, and the infusion center will bill an uninsured patient roughly $27,700 per visit at national average charges. The subcutaneous Keytruda Qlex costs the same or slightly more, and Opdivo costs about the same per year, so there is no cheaper checkpoint inhibitor to switch to.
The two levers that actually move the number are the Merck Patient Assistance Program, which can take the drug to zero at household incomes up to $79,800 for an individual, and the choice of infusion site, which moves the administration fee by nearly three times. If chemotherapy is part of the same regimen, what chemotherapy costs breaks out the drug and administration charges separately. For the staging and monitoring scans that come with immunotherapy, see PET scan costs and CT scan costs.